Thrombophilia and location of venous thromboembolism [3]

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 10, 2007, Pages 2151-2152

  Schulman, Sam ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HHS General Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN;

BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LEG THROMBOSIS; LETTER; LUNG EMBOLISM; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NORMAL VALUE; PHLEBOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SECONDARY PREVENTION; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

CARDIOLIPINS; FACTOR V; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PHLEBOGRAPHY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN; PULMONARY EMBOLISM; RISK; THROMBOPHILIA; VENOUS THROMBOSIS; VITAMIN K;

EID: 34548833298     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02718.x     Document Type: Letter

References (10)

1. de Moerloose P, Reber G, Perrier A, Perneger T, Bounameaux H. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol 2000; 110: 125-9.
2. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism -pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809-16.
3. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999; 81: 684-9.
4. Martinelli I, Battaglioli T, Razzari C, Mannucci PM. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost 2007; 5: 98-101.
5. Martinelli I, Cattaneo M, Panzeri D, Mannucci PM. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997; 77: 440-3.
6. Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004; 140: 330-7.
7. Klok FA, Huisman MV, Karami Djurabi R, Tormene D, Simioni P, Prandoni P. Factor V Leiden is associated with more distal location of deep vein thrombosis in the leg. J Thromb Haemost 2007; 5 (Suppl. 2): O-S-058.
8. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332: 1661-5.
9. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104: 332-8.
10. Schulman S, Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group. Thromb Haemost 1996; 75: 607-11.